Boston Scientific Investors Urged to Seek Lead Plaintiff Role in Securities Suit

Overview

• Rosen Law Firm is inviting Boston Scientific shareholders to move for lead plaintiff by May 4, 2026 in a federal securities class action.
• The lawsuit, already filed, alleges the company misled investors about the trajectory of its U.S. Electrophysiology business by touting growth that was not sustainable.
• Plaintiffs further claim new competitors cut into the company’s U.S. EP market share, which limited its growth potential.
• The notices cite a 17.6% share drop to $75.50 after Boston Scientific reported weaker U.S. EP sales and issued 2026 guidance below expectations, which the company linked to slower market growth and more competition.
• No class has been certified and the allegations are unproven, so investors may seek to lead the case, choose their own lawyer, or remain absent from the action.